Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Jun
11
Today In Oncology
Can AI Provide an Early Alert for Breast Cancer Before Diagnosis
Urologic Surgeon Sworn in as AMA President
Head and Neck Cancer HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC
Perioperative Serplulimab in PD-L1–Positive Gastric Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo